Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 15/20 | 0.53 |
| ▸ | KDM6B | O15054 | 7/20 | 0.53 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | KDM4A | O75164 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29952392 | 1.00 | KDM4C (0.53) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL28229192 | 0.87 | KDM4C (0.46) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL29955774 | 0.85 | KDM4C (0.48) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL4619119 | 0.85 | KDM4C (0.48) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL3284891 | 0.83 | TDP1 (0.50) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL10639037 | 0.83 | HIPK2 (0.40) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL13320901 | 0.83 | MAPT (0.44) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL116060 | 0.82 | KDM4C (0.55) | KDM4CKDM6BKDM4DKDM4EKDM4A | |
| SCHEMBL2847922 | 0.79 | ALDH1A1 (0.58) | KDM4CKDM4EALDH1A1KMT2ATDP1 | |
| SCHEMBL29467363 | 0.79 | ALDH1A1 (0.58) | KDM4CKDM4EALDH1A1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704830-A2 | MRGPRX2 INHIBITORS AND METHODS OF USE THEREOF | Septerna, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| WO-2024226914-A2 | MRGPRX2 ANTAGONISTS AND METHODS OF USE THEREOF | SEPTERNA, INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980908-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists and their use in treating opioid addiction and opioid induced constipation | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-12-18 | — | — | US | disclosed |
| US-8772308-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-8772308-B2 | Non-peptidyl, potent, and selective mu opioid receptor antagonists | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2014-07-08 | — | — | US | disclosed |
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2011-12-15 | — | — | US | disclosed |
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY | 2011-12-15 | — | — | US | disclosed |
| WO-2010083384-A2 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010062245-A1 | SPIROCYCLOBUTYL PIPERIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | ASTRAZENECA AB (SE) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4C 3552/4885KDM6B 2248/4885KDM4D 3386/4885 |
| US-20100130477-A1 | Spirocyclobutyl Piperidine Derivatives | HRH3, HRH4, HRH2 | KDM4C 1110/4885KDM6B 1390/4885KDM4D 1136/4885 |
| US-20110306628-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | KDM4C 4599/4885KDM6B 4407/4885KDM4D 4433/4885 |
| US-20140371255-A1 | NON-PEPTIDYL, POTENT, AND SELECTIVE MU OPIOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATING OPIOID ADDICTION AND OPIOID INDUCED CONSTIPATION | OPRM1, OPRK1, OPRL1 | KDM4C 4044/4885KDM6B 4578/4885KDM4D 4706/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4C 3552/4885KDM6B 2248/4885KDM4D 3386/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | KDM4C 3552/4885KDM6B 2248/4885KDM4D 3386/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4C 3552/4885KDM6B 2248/4885KDM4D 3386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.